ReviewPharmacology, biochemistry, and behavior2012
Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.
Review in Pharmacology, biochemistry, and behavior, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Glutamatergic candidate genes in autism spectrum disorder: an overview.Journal of neural transmission (Vienna, Austria : 1996) · 2014Pooled it
- Acupuncture for autism spectrum disorders (ASD).The Cochrane database of systematic reviews · 2011Pooled it
- Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study.Journal of autism and developmental disorders · 2021Trial
- Rare Variants in Purinergic P2X Receptor GenesHuman mutation · 2026Article
- The Use of Nutraceutical and Pharmacological Strategies in Murine Models of Autism Spectrum Disorder.Cells · 2024Review
- Effects of Walnut and Pumpkin on Selective Neurophenotypes of Autism Spectrum Disorders: A Case Study.Nutrients · 2023Review
- Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder.Frontiers in molecular neuroscience · 2023Review
- Altered Expression andCurrent neuropharmacology · 2022Article
- The State of the Dopaminergic and Glutamatergic Systems in the Valproic Acid Mouse Model of Autism Spectrum Disorder.Biomolecules · 2022Article
- A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.Experimental brain research · 2022Review
- Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic.Molecules (Basel, Switzerland) · 2022Review
- Abnormal sensory perception masks behavioral performance of Grin1 knockdown mice.Genes, brain, and behavior · 2022Article
- Effects of environmental enrichment and sexual dimorphism on the expression of cerebellar receptors in C57BL/6 and BTBR + Itpr3tf/J mice.BMC research notes · 2022Article
- Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission.International journal of molecular sciences · 2022Review
- Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report.EXCLI journal · 2022Article
- AMPA Receptor Function in Hypothalamic Synapses.Frontiers in synaptic neuroscience · 2022Review
- 8p21.3 deletions are rare causes of non-syndromic autism spectrum disorder.Neurogenetics · 2021Article
- Major motor and gait deficits with sexual dimorphism in a Shank3 mutant mouse model.Molecular autism · 2021Article
- Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research.Frontiers in neuroscience · 2021Review
- Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
There is strong evidence that metabotropic and ionotropic glutamate receptors are affected in autism spectrum disorders (ASD), but there are few candidate genes indicating involvement of these receptors. This suggests that glutamate receptor dysregulation may primarily be involved in the expression of ASD, but is an uncommon etiology. Directly implicated in models of fragile-X with ASD phenotypes is metabotropic glutamate receptor type 5 (mGluR5), which appears to be an effective pharmacologic target in a number of models of ASD. The review of other ASD models demonstrates that there is also evidence of a role for kainate, NMDA, and AMPA receptors in the neuropathophysiology of ASD, though the relationship between dysfunction in those receptors and ASD-associated phenotypes is not well understood. Current models indicate a way forward to delineate the role of glutamate receptors in ASD. Further development of preclinical models focusing on glutamate receptors may provide tools to target a clinically important subset of ASD symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.